BEAT-DKD

Biomarker enterprise to attack DKD

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 5
Grant agreement number
115974

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
15 085 937
EFPIA in kind
13 226 100
Other
797 001
Total Cost29 109 038

Summary

Diabetic kidney disease (DKD) is a common complication of diabetes, and DKD is now the most common form of chronic kidney disease. There is no effective way to prevent or treat DKD, leaving many patients in extremely poor health and facing high mortality rates. The BEAt-DKD project aims to deliver tools and knowledge that will facilitate the development of new, personalised treatments for DKD. Among other things, the project will identify and validate biological markers (biomarkers) to help researchers track whether a patient’s condition has worsened, and whether a treatment is working for them. They will also work to identify different sub-groups of patients that could respond differently to certain treatments. The results will therefore pave the way for the development of effective personalised treatments for DKD.

Achievements & News

Scientists identify five subtypes of diabetes
March 2018

Scientists have identified five subtypes of diabetes, a finding that will pave the way for more personalised treatments for the disease. The work, published in The Lancet Diabetes and Endocrinology, was funded in part by IMI through the projects BEAT-DKD and RHAPSODY. ###Currently, two main types of diabetes are recognised, and diagnosis is through a measurement of a patient’s blood sugar levels. In this study, scientists monitored over 13 000 newly-diagnosed diabetes patients, analysing blood sugar levels, insulin resistance, insulin secretion, and age of onset among other things. This revealed five distinct groups of patients with different risk levels for certain complications associated with diabetes. For example, patients in group 2 (‘severe insulin-deficient diabetes’) are at greatest risk of eye disease, while patients in group 3 (‘severe insulin-resistant diabetes’) had the highest incidence of kidney damage. ‘Current diagnostics and classification of diabetes are insufficient and unable to predict future complications or choice of treatment,’ said Leif Groop of Lund University in Sweden. ‘This is the first step towards personalised treatment of diabetes.’ Until now, the team has only studied people in Sweden and Finland; they now plan to carry out similar studies in China and India, to see if their findings apply in different ethnic groups.

Participants Show participants on map

EFPIA companies
  • AbbVie Inc., North Chicago, Illinois, United States
  • Astellas Pharma Europe BV, Leiden, Netherlands
  • Bayer AG, Berlin, Germany
  • Boehringer Ingelheim International GmbH, Ingelheim, Germany
  • Eli Lilly and Company Ltd, Basingstoke, United Kingdom
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Chu Hopitaux De Bordeaux, Talence, France
  • Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
  • Itä-Suomen yliopisto, Kuopio, Finland
  • Klinikum der Universitaet Regensburg, Regensburg, Germany
  • Lunds Universitet, Lund, Sweden
  • Medizinische Universitaet Wien, Vienna, Austria
  • Medizinische Universität Innsbruck, Innsbruck, Austria
  • SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland
  • The University of Exeter, Exeter, United Kingdom
  • Universitaetsklinikum Freiburg, Freiburg, Germany
  • Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany
  • University of Bristol, Bristol, United Kingdom
  • University of Dundee, Dundee, United Kingdom
  • University of Helsinki, University of Helsinki, Helsinki, Finland
  • University of Hull, Hull, United Kingdom
  • University of Leeds, Leeds, United Kingdom
  • University of Oxford, Oxford, United Kingdom
  • University of Turku, Turku, Finland
  • Università degli Studi di Bari Aldo Moro, Bari, Italy
  • Universitätsklinikum Erlangen, Erlangen, Germany
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Lipotype GmbH, Dresden, Germany
Associated partners
  • Jdrf International, New York, United States
Third parties
  • Apuliabiotech, Bari, Italy
  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
  • Varsinais-Suomen sairaanhoitopiirin kuntayhtymä (Turku University Hospital), Turku, Finland
Non EFPIA companies
  • University Of Michigan The Regents Of The University Of Michigan, Ann Arbor, United States

CONTACT

Project coordinator
Maria Gomez
Lunds universitet
Sweden
+46-40-39 10 58
maria.gomez[at]med.lu.se